Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution
Stopped early · Phase 1
Conditions studied: Healthy
In brief
The purpose of this study is to compare subjective drug liking using the Drug Rating Questionnaire, subject version (DRQ-S), question 2 and pharmacokinetics of Vyvanse™ and ADDERALL XR® when administered as an oral solution. Hypothesis: DRQ-S, question 2 will show no difference between the two drugs
Key facts
- Study ID
- NCT00776555
- Run by
- Shire
- People needed
- 3
- Starts
- 2008-11-21
- Expected to finish
- 2009-03-31
- Last updated by the study team
- 2021-06-09
Who can join
Age: 18 and older, up to 25. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy young adults, male or female (non-pregnant and non-lactating), age 18-25 years at time of consent
- Have a body mass index (BMI) between 20.0 and 29.0kg/m2
- Satisfactory medical assessment with no clinically significant or relevant
- Subject must demonstrate a positive response to amphetamine at Screening
You may not qualify if…
- A history of current or recurrent disease that could have an effect on the study
- Subject has a history of seizures, any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder
- Subject has a concurrent chronic or acute illness or other condition that might confound the results of safety assessments or that might increase risk to the subject
- Subject has any clinically significant ECG and/or laboratory abnormalities
- Subject has a documented allergy, hypersensitivity or intolerance to amphetamines
- Subject has been prescribed or has taken amphetamine products in the past, including childhood; recreational use may not be exclusionary per the Investigator's discretion
- Subject has a known family history of sudden cardiac death or ventricular arrhythmia
- Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine)
- Subject has participated in any investigational clinical or vaccine trial within 30 days prior to the first dose of study drug
- Subjects is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.